Oxidative modification of low-density lipoprotein (LDL) in HD patients: Role in electronegative LDL formation

Blood Purification

Volumn 18, Issue 3, 2000, Pages 169-176

  Ziouzenkova, Ouliana ^a   Sevanian, Alex ^b  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Apolipoprotein B 100; Dense LDL; Diabetes; Dityrosines; Electronegative LDL; Hemodialysis; Hemoglobin; Lipid peroxidation; Radical; Vitamin C; Vitamin E

Indexed keywords

ALKADIENE; ALPHA TOCOPHEROL; HEMOGLOBIN; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; PEROXIDASE;

ATHEROGENESIS; CARDIOVASCULAR RISK; HEMODIALYSIS; HUMAN; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW;

EID: 0033868408     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000014415     Document Type: Review

References (50)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
2. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T, Yamakido M: Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron 1997;76: 7-14.
3. Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H: Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997;131:229-236.
4. Blankestijn PJ: Hemodialysis using high flux membranes improves lipid profiles. Clin Nephrol 1994;42:S48-S51.
5. Koniger M, Quaschning T, Wanner C, Schollmeyer P, Kramer-Guth A: Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int Suppl 1999;71:S248-S250.
6. Quaschning T, Schomig M, Keller M, Thiery J, Nauck M, Schollmeyer P, Wanner C, Kramer-Guth A: Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 1999;10:332-341.
7. Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten ML, Heinecke J, Loseto-Wich G, Jürgens G, Sevanian A: Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood: Relevance to atherogenesis caused by hemodialysis. J Biol Chem 1999;274:18916-18924.
8. Sevanian A, Hwang J, Hodis HN, Cazzolato G, Avogaro P, Bittolo-Bon G: Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb 1996;16:784-793.
9. Demuth K, Myara I, Chappey B, Vedie B, Pech-Amsellem MA, Haberland ME, Moatti N: A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 1996;16:773-783.
10. Horkko S, Huttunen K, Kesaniemi YA: Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 1995;47:1732-1740.
11. Tetta C, Segoloni G, Mariano F, Montrucciho G, Turello E, Camussi G: Leukocyte-derived mediators and biocompatibility. Nephrol Dial Transplant 1991; 6(suppl 2):24-30.
12. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PW, Selhub J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis 1995;114:93-103.
13. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999;55:389-399.
14. - is a lipid peroxide-enriched circulating lipoprotein. J Lipid Res 1997;38:419-428.
15. Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E: Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem 1977;252:7279-7287.
16. Weisgraber KH, Innerarity TL, Mahley RW: Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 1978;253:9053-9062.
17. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, Berliner JA, Friedman P, Dennis EA, Curtiss LK, Palinski W, Witztum JL: Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage up-take of oxidized low-density lipoproteins. J Clin Invest 1999;103:117-128.
18. Esterbauer H, Gebicki J, Puhl H, Jürgens G: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992;13:341-390.
19. Chang YH, Abdalla DSP, Sevanian A: Characterization of cholesterol oxidation products formed by oxidative modification of low-density lipoprotein. Free Radic Biol Med 1996;23:202-214.
20. Toborek M, Wasik T, Drozdz M, Klin M, Magner-Wrobel K, Kopieczna-Grezebieniak E: Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 1992;41:1229-1232.
21. Sanaka T, Higuchi C, Shinobe T, Nishimura H, Omata M, Nihei H, Sugino N: Lipid peroxidation as an indicator of biocompatibility in haemodialysis. Nephrol Dial Transplant 1995;10(suppl 3):34-38.
22. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW: Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia? Kidney Int 1998; 54:1290-1295.
23. Sutherland HF, Walker RJ, Ball MJ, Stapley SA, Robertson MC: Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995;48:227-236.
24. Hecker M, Haurand M, Ullrich V, Dkzfalusy U, Hamarstrom S: Products, kinetics, and substrate specificity of homogeneous thromboxane synthase from human platelets: Development of a novel enzyme assay. Arch Biochem Biophys 1987;254:124-135.
25. Ylikorkala O, Huttunen K, Jarvi J, Viinikka L: Prostacyclin and thromboxane in chronic uremia: Effect of hemodialysis. Clin Nephrol 1982;18:83-87.
26. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-888.
27. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G: Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 1994;46:869-876.
28. Yla-Herttuala S, Palinski W, Rosenfeld M, Parthasarathy S, Carew T, Butler S, Witztum J, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions. J Clin Invest 1989;84:1086-1095.
29. Banni S, Lucchi L, Baraldi A, Botti B, Cappelli G, Corongiu F, Dessi MA, Tomasi A, Lusvarghi E: No direct evidence of increased lipid peroxidation in hemodialysis patients. Nephron 1996;72:177-183.
30. Carbonneau MA, Peuchant E, Sess D, Canioni P, Clerc M: Free and bound malondialdehyde measured as thiobarbituric acid adduct by HPLC in serum and plasma. Clin Chem 1991;37:1423-1429.
31. Heinecke JW: Is lipid peroxidation relevant to atherogenesis? J Clin Invest 1999;104:135-136.
32. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996;20:707-727.
33. Giessauf A, Van Wickern B, Simat T, Steinhart H, Esterbauer H: Formation of N-formylkynurenine suggests the involvement of apolipoprotein B-100 centered tryptophan radicals in the initiation of LDL lipid peroxidation. FEBS Lett 1996;389:136-140.
34. Witko-Sarsat V, Friedlander M, Capeiliere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, DescampsLatscha: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49: 1304-1313.
35. Kramer-Guth A, Quaschning T, Galle J, Baumstark MW, Koniger M, Mauck P, Schollmeyer P, Marz W, Wanner C: Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes. Eur J Clin Invest 1997; 27:460-468.
36. -) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 1998;35:161-164.
37. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
38. Tertov VV, Bittolo-Bon G, Sobenin IA, Cazzolato G, Orekhov AN, Avogaro P: Naturally occurring modified low density lipoproteins are similar if not identical: More electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol 1995;62:166-172.
39. Lucchi L, Cappelli G, Acerbi MA, Spattini A, Lusvarghi E: Oxidative metabolism of polymorphonuclear leukocytes and serum opsonic activity in chronic renal failure. Nephron 1989;51:44-50.
40. Gündüz Z, Düsünsel R, Köse K, Utas C, Dogan P: The effects of dialyzer reuse on plasma antioxidative mechanisms in patients on regular hemodialysis treatment. Free Radic Biol Med 1996;21:225-231.
41. Hazell LJ, Davies MJ, Stocker R: Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins. Biochem J 1999;339:489-495.
42. Jacob JS, Cistola DP, Hsu FF, Muzaffar S, Mueller DM, Hazen SL, Heinecke JW: Human phagocytes employ the myeloperoxidase-hydrogen peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and isodityrosine by a tyrosyl radical-dependent pathway. J Biol Chem 1996;271:19950-19956.
43. Hazen SL, Hsu FF, Heinecke JW: p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. J Biol Chem 1996;271:1861-1867.
44. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW: Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997;272:3520-3526.
45. Miller YI, Felikman Y, Shaklai N: Hemoglobin-induced apolipoprotein B cross-linking in low-density lipoprotein peroxidation. Arch Biochem Biophys 1996;326:252-260.
46. Seukeran D, Fletcher S, Sellars L, Vestey JP: Sudden deepening of pigmentation during haemodialysis due to severe haemolysis. Br J Dermatol 1997;137:997-999.
47. Daul AE, Schafers RF, Wenzel RR, Loew H. Windeck R, Philipp T: Acute hemolysis with subsequent life-threatening pancreatitis in hemodialysis. A complication which is not preventable with current dialysis equipment. Dtsch Med Wochenschr 1994;119:1263-1269.
48. Wang J, Huang CJ, Chow CK: Red cell vitamin E and oxidative damage: A dual role of reducing agents. Free Radic Res 1996;24:291-298.
49. Lubrano R, Taccone-Gallucci M, Mazzarella V, Bandino D, Citti G, Elli M, Giardini O, Casciani CU: Relationship between red blood cell lipid peroxidation, plasma hemoglobin, and red blood cell osmotic resistance before and after vitamin E supplementation in hemodialysis patients. Artif Organs 1986;10:245-248.
50. Miller YI, Alamentova SM, Shaklai M: Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: Antioxidant role of haptoglobin. Biochemistry 1997;36:12189-12198.